Kura Oncology

Q2 FY2026 EarningsQ2 FY2026 results were mixed as revenue of $20.9M beat the $20.2M consensus (+3.4%), driven by a 57% QoQ surge in KOMZIFTI® product sales. Despite the top-line beat, GAAP EPS of -$0.77 was significantly better than the -$0.89 expected, primarily due to lower-than-anticipated R&D spend and strong interest income. Management confirmed a robust cash position of $519M, sufficient to fund operations through pivotal Phase 3 readouts in 2028.